Sticking Point: Novartis Menveo Vaccine Faces Delay Over FDA Request For Info
This article was originally published in The Pink Sheet Daily
Executive Summary
Although only a few months are at stake, this is the second setback this year for the product, which Novartis hopes will validate its vaccine investments.
You may also be interested in...
One More Shot? The ACIP Continues Its Review Of Meningitis Vaccines
When the CDC's Advisory Committee on Immunization Practices meets in Atlanta on Feb. 25, the working group will edge closer to making a difficult decision - whether a trio of vaccines to treat meningitis eventually should be recommended routinely for infants and toddlers less than two years of age
One More Shot? The ACIP Continues Its Review Of Meningitis Vaccines
When the CDC's Advisory Committee on Immunization Practices meets in Atlanta on Feb. 25, the working group will edge closer to making a difficult decision - whether a trio of vaccines to treat meningitis eventually should be recommended routinely for infants and toddlers less than two years of age
Novartis Needs A Bigger Safety Database For Menveo, FDA Says
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.